RedHill Biopharma Ltd. (RDHL) said Wednesday that the U.S. Food and Drug Administration or FDA has granted Fast Track designation to RHB-204 for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC). This is a rare disease for which there is no FDA-approved first-line therapy.
The FDA's Fast Track designation is intended to help progress development and speed up the review of novel therapies for serious conditions for which there is an unmet medical need.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.